Better Therapeutics Inc
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease… Read more
Better Therapeutics Inc (BTTX) - Net Assets
Latest net assets as of September 2023: $-9.94 Million USD
Based on the latest financial reports, Better Therapeutics Inc (BTTX) has net assets worth $-9.94 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($10.72 Million) and total liabilities ($20.66 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-9.94 Million |
| % of Total Assets | -92.68% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Better Therapeutics Inc - Net Assets Trend (2019–2022)
This chart illustrates how Better Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Better Therapeutics Inc (2019–2022)
The table below shows the annual net assets of Better Therapeutics Inc from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $-899.00K | -102.45% |
| 2021-12-31 | $36.72 Million | +643.36% |
| 2020-12-31 | $-6.76 Million | -1017.02% |
| 2019-12-31 | $-605.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Better Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8648200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $110.60 Million | % |
| Total Equity | $-899.00K | 100.00% |
Better Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Better Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Leiner Pak Gelatine Ltd
KAR:LPGL
|
$2.45K |
|
Adamjee Insurance Company Ltd
KAR:AICL
|
$2.45K |
|
Asia Pacific Securities JSC
VN:APS
|
$2.45K |
|
SFS REAL ESTATE INVESTMENT TRUST
XNSA:SFSREIT
|
$2.45K |
|
Arma Services Inc
PINK:ARMV
|
$2.45K |
|
Viet Tien Son Real Estate Holding Co
VN:AAV
|
$2.45K |
|
TDT Investment and Development JSC
VN:TDT
|
$2.45K |
|
Janana De Malucho Textile Mills Ltd
KAR:JDMT
|
$2.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Better Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 36,720,000 to -899,000, a change of -37,619,000 (-102.4%).
- Net loss of 39,760,000 reduced equity.
- Other factors increased equity by 2,141,000.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.76 Million | -4422.69% |
| Other Changes | $2.14 Million | +238.15% |
| Total Change | $- | -102.45% |
Book Value vs Market Value Analysis
This analysis compares Better Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.03 | $0.00 | x |
| 2020-12-31 | $-0.89 | $0.00 | x |
| 2021-12-31 | $1.56 | $0.00 | x |
| 2022-12-31 | $-0.04 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Better Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-27.46%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -32194.44% | 0.00x | 0.00x | $-5.73 Million |
| 2020 | 0.00% | -79837.50% | 0.00x | 0.00x | $-5.71 Million |
| 2021 | -109.84% | 0.00% | 0.00x | 1.39x | $-44.01 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-39.67 Million |
Industry Comparison
This section compares Better Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Better Therapeutics Inc (BTTX) | $-9.94 Million | 0.00% | N/A | $2.45K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |